Back to Search
Start Over
Dutasteride, the dual 5?-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line
- Source :
- The Prostate. 58:130-144
- Publication Year :
- 2004
- Publisher :
- Wiley, 2004.
-
Abstract
- Background Reduction of T to DHT by 5alphaR in the prostate enhances androgenic activity for most targets. Inhibition of 5alphaR activity with finasteride attenuates androgen action in men and animal models. The objective of this study was to compare and contrast the effects of a potent new 5alphaR inhibitor, dutasteride, with finasteride in the LNCaP prostate cancer cell line. Methods LNCaP cells were incubated for varying times with T or DHT in steroid-free medium in the absence or presence of increasing doses of dutasteride or finasteride and the effects on 5alphaR activity, PSA accumulation in the medium, and on cell proliferation were determined. Drug effects on apoptosis were investigated using Annexin V staining and a cell death ELISA assay. Effects of the drugs on AR ligand-binding activity and on AR protein levels were determined. Results Dutasteride inhibited (3)H-T conversion to (3)H-DHT and, as anticipated, inhibited T-induced secretion of PSA and proliferation. However the drug also inhibited DHT-induced PSA secretion and cell proliferation (IC(50) approximately 1 microM). Finasteride also inhibited DHT action but was less potent than dutasteride. Dutasteride competed for binding the LNCaP cell AR with an IC(50) approximately 1.5 microM. High concentrations of dutasteride (10-50 microM), but not finasteride, in steroid-free medium, resulted in enhanced cell death, possibly by apoptosis. This was accompanied by loss of AR protein and decreased AR ligand-binding activity. Occupation of AR by R1881 partly protected against cell death and loss of AR protein. PC-3 prostate cancer cells, which do not contain AR, also were killed by high concentrations of dutasteride, as well as by 50 microM finasteride. Conclusions Dutasteride exhibited some inhibitory actions in LNCaP cells possibly related to 5alphaR inhibition but also had antiandrogenic effects at relatively low concentrations and cell death-promoting effects at higher concentrations. Finasteride also was antiandrogenic, but less than dutasteride. The antiandrogenic effects may be mediated by the mutant LNCaP cell AR. Promotion of cell death by dutasteride can be blocked, but only in part, by androgens.
- Subjects :
- Male
medicine.medical_specialty
medicine.drug_class
Urology
Apoptosis
Enzyme-Linked Immunosorbent Assay
Ligands
urologic and male genital diseases
Antiandrogen
5 Alpha-Reductase Inhibitor
chemistry.chemical_compound
5-alpha Reductase Inhibitors
3-Oxo-5-alpha-Steroid 4-Dehydrogenase
Internal medicine
LNCaP
Tumor Cells, Cultured
medicine
Humans
Testosterone
Enzyme Inhibitors
music
music.instrument
Dose-Response Relationship, Drug
Cell growth
business.industry
Finasteride
Prostatic Neoplasms
Androgen Antagonists
Dutasteride
Prostate-Specific Antigen
Azasteroid
Endocrinology
Oncology
chemistry
Receptors, Androgen
Azasteroids
business
Cell Division
Subjects
Details
- ISSN :
- 10970045 and 02704137
- Volume :
- 58
- Database :
- OpenAIRE
- Journal :
- The Prostate
- Accession number :
- edsair.doi.dedup.....67b12240276d828035554be14d3fbb44
- Full Text :
- https://doi.org/10.1002/pros.10340